Previously recorded as Cycloporters, Inc. (to 2018)
Eight patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2035. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2035
Next term end
4
Patent families
When these terms end
Each bar runs from grant to computed term end. 2020 to 2043.
US 11,168,310
Compositions and Methods for Treating Mitochondrial Neurogastrointestinal Encephalopathy
Feb 22, 2039
US 12,698,482
Compositions and Methods for Treating Mitochondrial Neurogastrointestinal Encephalopathy
Feb 22, 2039
US 11,987,821
Compositions and Methods for Treating Mitochondrial Neurogastrointestinal Encephalopathy
Aug 30, 2039
20252030203520402043
20 pending applications: term is not computable until grant.Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jun 2036 · High confidence
Also notable
Ends Feb 2039 · Medium confidence
Also notable
Ends May 2043 · High confidence
Cell Penetrating Peptides and Methods of Making and Using Thereof
US 10,626,147
The most cited patent in this portfolio, cited by 70 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2036.
Compositions and Methods for Treating Mitochondrial Neurogastrointestinal Encephalopathy
US 11,168,310
Cited by 8 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2039.
Compositions for Delivery of Antisense Compounds
US 12,741,989
Granted 2026. Too new for citation comparison; protection runs to 2043.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Oct 21, 2027The maintenance fee for Cell Penetrating Peptides and Methods of Making and Using Thereof (US 10,626,147) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 21, 2026
What they patent
The 3 largest of its 4 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Compositions and Methods for Treating Mitochondrial Neurogastrointestinal Encephalopathy | 3 in force | to Aug 2039 |
| Cell Penetrating Peptides and Methods of Making and Using Thereof | 3 in force | to Jun 2036 |
| Compositions for Delivery of Antisense Compounds | 1 in force | to May 2043 |
Patents held now
Soonest term end first.
Showing 1 to 8 of 8
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,225,506 | Cell Penetrating Peptides and Methods of Making and Using Thereof In force · High confidence | In force | High confidence | |
| US 10,815,276 | Cell Penetrating Peptides and Methods of Making and Using Thereof In force · High confidence | In force | High confidence | |
| US 10,626,147 | Cell Penetrating Peptides and Methods of Making and Using Thereof In force · High confidence | In force | High confidence | |
| US 11,168,310 | Compositions and Methods for Treating Mitochondrial Neurogastrointestinal Encephalopathy In force · Medium confidence | In force | Medium confidence | |
| US 12,698,482 | Compositions and Methods for Treating Mitochondrial Neurogastrointestinal Encephalopathy In force · Low confidence | In force | Low confidence | |
| US 11,987,821 | Compositions and Methods for Treating Mitochondrial Neurogastrointestinal Encephalopathy In force · Medium confidence | In force | Medium confidence | |
| US 12,378,267 | Synthesis of Fmoc-Protected Morpholino Monomers and Oligomers In force · High confidence | In force | High confidence | |
| US 12,741,989 | Compositions for Delivery of Antisense Compounds In force · High confidence | In force | High confidence |
Also on record, not counted in the 8: 20 applications pending · 4 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.